IOL | Ophthalmology Innovation Source

MEDICEM

MEDICEM is a group of biomedical companies focusing on research, development and commercialization of medical devices. Our WIOL–CF Bioanalogic Polyfocal IOL, represents new step in evolution of IOLs for the patients with cataract and presbyopia. WIOL-CF offers vision to all distances, including restored reading capability, in all light conditions. www.medicem.com

AcuFocus

AcuFocus is committed “to continuously adapting and expanding” its small aperture technology. The company’s first device, the KAMRA, received US regulatory approval in April 2015, and the firm has begun a slow launch. In development is the IC-8 intraocular lens (IOL). To date, AcuFocus has “extensive clinical data” on about 200 patients. The IC-8 already…

ClarVista Medical

ClarVista is a privately held, clinical- and commercial-stage ophthalmology device company concentrating solely on the development of the Harmoni modular intraocular lens (IOL) system. While surgical instrumentation and biometry devices have rapidly progressed and improved in the past decade, the fundamental design of the IOL has not. Surgeons (and patients) have, therefore, come to tolerate…

PowerVision

PowerVision has developed “the first true shape-changing, fluid driven intraocular lens (IOL),” CEO Barry Cheskin said. The FluidVision IOL creates a “continuously variable monofocal” where no light is split as is currently the case with multifocal lenses. The lens mimics the eye’s natural accommodative power to transport fluids inside it, which creates the shape change.…

Looking Deep at Extended Depth-of-Focus IOLs

Multifocal IOLs, perhaps the best established solution to the problem of enabling post-cataract patients to see clearly at all distances, work by incorporating discrete refractive optical zones or diffractive echelettes into the lens. Accommodating IOLs, which aim to provide the same benefit, use ciliary muscle power to move the lens and/or change its shape to…

Premium IOLs: Two Outliers with Mainstream Potential

A problem that plagues refractive cataract surgery is the difficulty of determining the IOL power that will achieve each patient’s refractive target. In the old days, if a post-cataract patient wasn’t satisfied with their vision, they simply wore a pair of glasses. But patients paying thousands of dollars for a premium IOL are not satisfied…

A Look at Premium IOLs

Can Accommodating IOLs Fuel Demand? For nearly two decades, “presbyopia-correcting” intraocular lenses (IOLs) have been available to post-cataract surgery patients, but for a variety of reasons they have garnered only modest interest. According to Market Scope, presbyopia-correcting lenses only account for 2.4% of total IOLs implanted globally in 2014. Moreover, use of these IOLs has…

ClarVista’s Two-Part Strategy To Premium IOLs

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 053″] CEO Paul McLean and Medical Director Malik Kahook, MD, explain how they’ll bring Harmoni to the IOL market. Podcast Guest Paul McLean Paul McLean is President and CEO of ClarVista Medical. ClarVista Medical is clinical stage, ophthalmic device Start-up Company focused on the development of the HARMONI modular intra-ocular lens…

Calhoun Vision Stages Turnaround

Medtech companies in ophthalmology have made some significant strides in recent months. Second Sight and Glaukos, of course, staged IPOs in their pursuit of revolutionary ophthalmic devices. Oculeve excited Dry Eye leader Allergan enough to warrant a significant acquisition offer, bringing the highly promising neurostim device in-house where it may someday complement Restasis. Now we’re…

Spotlight on Presbyopia – Market Overview

Participant: Richard Lindstrom, MD Dr. Lindstrom is a board-certified ophthalmologist and internationally recognized leader in corneal, cataract, refractive and laser surgery. View Full Profile

Spotlight on Presbyopia

Participants: Gilbert H. Kliman, MD Dr. Gil Kliman leads the medical device investment team at InterWest Partners and invests in a broad array of healthcare opportunities, with a special interest in ophthalmology and digital health. View Full Profile Malvina B. Eydelman, MD Dr. Eydelman has been involved in all aspects of assuring the safety and…

Sharklet Technologies

Sharklet Technologies has incorporated technology derived from the shark’s ability to remain bacteria-free into a patterned protective membrane. To date, there is “strong in vivo results” showing the lens can facilitate the growth of human lens epithelial cells outside the visual axis, thus eliminating PCO. In lab analyses, when there is a smooth surface, cells…